From GlobeNewswire: 2025-02-18 01:00:00

Valneva SE exceeded 2024 growth targets with a 13% increase in sales revenue and a 10% increase in total revenues compared to 2023. The year-end cash position was strong at €168.3 million. The company made substantial clinical and regulatory progress, leading to multiple data readouts, product approvals, and label extensions in 2025.

Looking ahead to 2025, Valneva SE expects solid revenue growth, positive commercial cash flows, and strategic R&D investments with lower operating cash burn. Sales revenues are projected to grow to €170-180 million, total revenues to reach €180-190 million, and R&D investments to be between €90 – €100 million.

Valneva SE’s Chief Financial Officer, Peter Bühler, highlighted the company’s successful 2024 performance, setting the stage for key catalysts in 2025. The company made progress in its Lyme disease program, secured additional regulatory approvals for its chikungunya vaccine, and expanded its clinical pipeline with a tetravalent Shigella vaccine candidate.

Key upcoming catalysts for Valneva SE include the first data readout from the Lyme disease Phase 3 study by the end of 2025, further chikungunya vaccine approvals, and the initiation of a Phase 3 pediatric trial for IXCHIQ®. The company will also release Phase 2b efficacy data for its Shigella vaccine candidate and Phase 1 results for its Zika vaccine candidate in 2025.



Read more at GlobeNewswire:: Valneva Reports Preliminary Unaudited 2024 Revenue and Cash